Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP03
- Development stage
- Phase 4
- Lead developer
- Avalyn Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AP03 is Avalyn Pharma's preclinical inhaled fixed-dose combination of nintedanib + pirfenidone for pulmonary fibrosis. It is designed for aerosolized lung delivery to combine pirfenidone's antifibrotic and anti-inflammatory activity with nintedanib's inhibition of profibrotic receptor tyrosine kinase signaling, while aiming to reduce the systemic tolerability limitations associated with combining the oral medicines. Avalyn reported that a Phase 1 study was planned to begin by the end of 2026. (avalynpharma.com)
02
Targets
FGFR (Fibroblast growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)TGFBR1LCK (Proto-oncogene tyrosine-protein kinase Lck)LYN (LYN proto-oncogene, Src family tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on AP03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP03.